Importance of peak PRA in predicting the kidney transplant survival in highly sensitized patients

被引:34
作者
Singh, D [1 ]
Kiberd, BA [1 ]
West, KA [1 ]
Kamal, K [1 ]
Balbontin, F [1 ]
Belitsky, P [1 ]
Lawen, J [1 ]
机构
[1] Queen Elizabeth II HLth Sci Ctr, Kidney Transplant Program, Halifax, NS B3H 2Y9, Canada
关键词
D O I
10.1016/j.transproceed.2003.08.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Do patients with high historic peak panel-reactive antibodies (PRA) remain high risk if their PRA levels fall before transplantation? We examined retrospectively 406 first and repeat kidney recipients with a peak PRA of >50%, who were transplanted from our center between January 1990 and December 2001. Univariate analysis by log-rank test was performed for variables that affect graft survival. The factors tested included current PRA, peak PRA, difference between peak and current PRA (DeltaPRA), HLA mismatch, gender, age, transplant number, and donor source. Receiver operator characteristic curves (ROC) were generated to obtain the best cutpoints for current PRA and DeltaPRA. Current PRA (P < .0001), peak PRA (P = .0004), and DeltaPRA (P = .0015) were significant predictors by univariate analysis. However, in a multivariate model, peak PRA was not significant. Current PRA (P < .0001) was significantly associated with graft survival, while OPRA showed a strong trend to significance (P = .05). Current PRA of <26% and DeltaPRA of >37% were the best cutpoints for separating good and poor outcomes. This study shows that current PRA and OPRA impact on graft survival in highly sensitized (>50%) patients. Sensitized patients with peak PRA >50% who subsequently have a drop in PRA to <26% are at lower risk of graft loss than those with a persistently high PRA. A fall in peak PRA of >37% at the time of transplant appears to be of benefit only in those patients who achieve a current PRA of <26%.
引用
收藏
页码:2395 / 2397
页数:3
相关论文
共 7 条
[1]   Effect of recipient sensitization (peak PRA) on graft outcome in haploidentical living related kidney transplants [J].
Barama, A ;
Oza, U ;
Panek, R ;
Belitsky, P ;
MacDonald, AS ;
Lawen, J ;
McAlister, V ;
Kiberd, B .
CLINICAL TRANSPLANTATION, 2000, 14 (03) :212-217
[2]   Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching [J].
Bryan, CF ;
Baier, KA ;
Nelson, PW ;
Luger, AM ;
Martinez, J ;
Pierce, GE ;
Ross, G ;
Shield, CF ;
Warady, BA ;
Aeder, MI ;
Helling, TS ;
Muruve, N .
TRANSPLANTATION, 1998, 66 (12) :1827-1832
[3]   RENAL-TRANSPLANTATION DESPITE A POSITIVE ANTIGLOBULIN CROSS-MATCH WITH AND WITHOUT PROPHYLACTIC OKT3 [J].
DAFOE, DC ;
BROMBERG, JS ;
GROSSMAN, RA ;
TOMASZEWSKI, JE ;
ZMIJEWSKI, CM ;
PERLOFF, LJ ;
NAJI, A ;
ASPLUND, MW ;
ALFREY, EJ ;
SACK, M ;
ZELLERS, L ;
KEARNS, J ;
BARKER, CF .
TRANSPLANTATION, 1991, 51 (04) :762-768
[4]   CADAVER RENAL-TRANSPLANTATION IGNORING PEAK-REACTIVE SERA IN PATIENTS WITH MARKEDLY DECREASING PRETRANSPLANT SENSITIZATION [J].
SANFILIPPO, F ;
VAUGHN, WK ;
SPEES, EK ;
BOLLINGER, RR .
TRANSPLANTATION, 1984, 38 (02) :119-124
[5]  
Speiser D E, 1995, Transpl Immunol, V3, P330
[6]   THE RELEVANCE OF A MORE SENSITIVE CROSSMATCH ASSAY TO RENAL-TRANSPLANTATION [J].
TALBOT, D ;
GIVAN, AL ;
SHENTON, BK ;
STRATTON, A ;
PROUD, G ;
TAYLOR, RMR .
TRANSPLANTATION, 1989, 47 (03) :552-555
[7]  
ZHOU YC, 1991, CLIN TRANSPLANT, V20, P313